Edding Genor Boosts Profit as Landmark Biotech Merger Drives New Growth

Genor Biopharma Holdings Limited ( (HK:6998) ) has shared an announcement.

Edding Genor Group reported revenue of RMB2,487.5 million for 2025, with net profit rising to RMB399.3 million and cash and cash equivalents climbing to RMB1,054.9 million by year-end, indicating strengthened financial resilience. Adjusted net profit reached RMB470.6 million and adjusted EBITDA RMB950.4 million, underscoring improved underlying profitability after excluding non-cash and transaction-related items.

The year was defined by the completion of a strategic merger between Genor Biopharma and Edding Group, creating the first reverse takeover involving a biotech company under Hong Kong’s Chapter 18A and reshaping the company’s governance and management structure. Post-merger, the group accelerated commercialisation and R&D, highlighted by NMPA approval for breast cancer drug Rujianing and the inclusion of six innovative products, including Rujianing, Jing Zhu Da, Vascepa and Mulpleta, in China’s National Reimbursement Drug List, which is expected to fuel future sales growth.

The most recent analyst rating on (HK:6998) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Genor Biopharma Holdings Limited stock, see the HK:6998 Stock Forecast page.

More about Genor Biopharma Holdings Limited

Edding Genor Group Holdings Limited is a biopharmaceutical company formed through the merger of Genor Biopharma Holdings Limited and Edding Group Company Limited. The group now operates a diversified portfolio spanning oncology, autoimmune, cardiovascular, respiratory and anti-infective therapies, with seven commercialised products, three clinical-stage assets and multiple preclinical pipelines targeting both domestic and global healthcare markets.

Average Trading Volume: 1,284,721

Technical Sentiment Signal: Sell

Current Market Cap: HK$4.92B

Learn more about 6998 stock on TipRanks’ Stock Analysis page.